2. Vías de señalización
  3. Metabolic Enzyme/Protease
  4. Cytochrome P450
  5. CYP17A1 Isoform

CYP17A1

CYP17A1 is a cytochrome P450 enzyme that drives steroidogenesis by catalyzing 17α-hydroxylation and 17,20-lyase reactions required for androgen precursor formation[1]. Mechanistically, this dual activity connects pregnenolone and progesterone metabolism with androgen biosynthesis, making CYP17A1 central to steroid hormone research[1][2]. In disease models, CYP17A1 supports androgen production relevant to castration-resistant prostate cancer, where abiraterone suppresses tumor growth by inhibiting this steroidogenic enzyme[3]. Compared with teleost Cyp17a2, which shows only 17α-hydroxylase activity, Cyp17a1 retains both 17α-hydroxylase and 17,20-lyase activities, supporting isoform-specific experimental design[4]. For inhibitor research, abiraterone and TOK-001 structures reveal active-site binding features useful for CYP17A1 drug-design studies, while non-steroidal CYP17A1 inhibitors support selectivity-focused medicinal chemistry[5][6].

CYP17A1 Produits associés (4):

Cat. No. Nom du produit Effet Pureté
  • HY-148430
    4-Pyridylmethyl adamantanecarboxamide
    		Inhibitor 99.83%
    4-Pyridylmethyl adamantanecarboxamide (Compound 11) is an Aromatase inhibitor with an IC50 of 1.5 μM against hAromatase. 4-Pyridylmethyl adamantanecarboxamide inhibits the C17,20-lyase activity of testicular cytochrome P45017α with an IC50 of 1600 nM, and also inhibits the 17α-hydroxylase activity of this enzyme with an IC50 of 7700 nM. 4-Pyridylmethyl adamantanecarboxamide can be used in the research of prostate cancer.
  • HY-163359
    CYP17A1/HDAC6-IN-1
    		Inhibitor
    CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1/HDAC6, with IC50 of 0.284μM and 0.6015 μM,respectively. CYP17A1/HDAC6-IN-1 has anti-tumor activity.
  • HY-164457
    ASN-001
    		Inhibitor
    ASN-001 is an orally active CYP-17A1 lyase inhibitor that selectively inhibits testosterone synthesis. ASN-001 has anticancer activity and can be used for research in the field of prostate cancer.
  • HY-181045
    CYP17A1-IN-2
    		Inhibitor
    CYP17A1-IN-2 is a potent inhibitor of CYP17A1. CYP17A1-IN-2 exhibits anti-proliferative activity against prostate cancer cells. CYP17A1-IN-2 can be used in research related to castration-resistant prostate cancer.